BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 109.537
EU - Europa 58.136
AS - Asia 46.292
SA - Sud America 7.959
AF - Africa 904
OC - Oceania 397
Continente sconosciuto - Info sul continente non disponibili 63
Totale 223.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 107.537
SE - Svezia 21.006
SG - Singapore 14.276
GB - Regno Unito 11.015
CN - Cina 10.967
IT - Italia 8.014
BR - Brasile 6.558
HK - Hong Kong 6.351
VN - Vietnam 4.592
DE - Germania 3.418
FI - Finlandia 3.167
PL - Polonia 3.167
BD - Bangladesh 2.722
TR - Turchia 2.083
UA - Ucraina 1.915
RU - Federazione Russa 1.682
FR - Francia 1.648
KR - Corea 1.196
BG - Bulgaria 888
CA - Canada 792
IN - India 768
ID - Indonesia 617
NL - Olanda 513
AR - Argentina 468
JP - Giappone 466
BZ - Belize 402
MX - Messico 396
AU - Australia 375
IQ - Iraq 364
ES - Italia 276
AE - Emirati Arabi Uniti 270
IE - Irlanda 262
AT - Austria 252
PK - Pakistan 243
ZA - Sudafrica 225
CO - Colombia 193
EC - Ecuador 192
UZ - Uzbekistan 154
VE - Venezuela 154
MA - Marocco 148
CL - Cile 132
MY - Malesia 119
LT - Lituania 116
PH - Filippine 104
CZ - Repubblica Ceca 103
SA - Arabia Saudita 103
JO - Giordania 98
EG - Egitto 97
BE - Belgio 95
KE - Kenya 94
NP - Nepal 91
TN - Tunisia 81
AZ - Azerbaigian 78
CH - Svizzera 77
RO - Romania 77
TH - Thailandia 77
JM - Giamaica 76
DZ - Algeria 73
PY - Paraguay 73
TW - Taiwan 71
IL - Israele 66
BO - Bolivia 64
CR - Costa Rica 63
PE - Perù 62
UY - Uruguay 59
KZ - Kazakistan 52
PT - Portogallo 50
RS - Serbia 49
GE - Georgia 46
DO - Repubblica Dominicana 45
GR - Grecia 45
IR - Iran 45
OM - Oman 39
BY - Bielorussia 37
EU - Europa 36
TT - Trinidad e Tobago 35
HN - Honduras 34
AL - Albania 33
HR - Croazia 32
DK - Danimarca 31
SN - Senegal 30
GT - Guatemala 28
LB - Libano 28
PA - Panama 27
KG - Kirghizistan 26
ET - Etiopia 25
BH - Bahrain 24
PS - Palestinian Territory 24
HU - Ungheria 23
QA - Qatar 23
SI - Slovenia 22
BA - Bosnia-Erzegovina 21
SK - Slovacchia (Repubblica Slovacca) 21
NI - Nicaragua 20
MD - Moldavia 19
PR - Porto Rico 19
AO - Angola 18
NG - Nigeria 18
NZ - Nuova Zelanda 18
NO - Norvegia 17
Totale 222.941
Salva come PNG Salva come JPEG
Città #
Stockholm 18.328
Fairfield 12.856
Ashburn 10.838
Singapore 9.191
Santa Clara 7.849
Woodbridge 7.526
Southend 7.258
Hong Kong 6.184
Houston 5.938
Seattle 5.004
Cambridge 4.158
Wilmington 4.152
Chandler 4.145
San Jose 4.077
Jacksonville 3.674
Hefei 3.258
Warsaw 3.013
Helsinki 2.824
Ann Arbor 2.816
London 2.619
Dearborn 2.335
Beijing 2.066
New York 1.883
The Dalles 1.746
Council Bluffs 1.634
Modena 1.527
Nyköping 1.463
Ho Chi Minh City 1.407
Los Angeles 1.389
San Diego 1.261
Izmir 1.225
Chicago 1.177
Seoul 1.152
Hanoi 1.137
Milan 942
Princeton 893
Sofia 863
Dallas 859
Lauterbourg 792
Eugene 730
Buffalo 716
Moscow 534
São Paulo 530
Columbus 511
Jakarta 478
Boardman 461
Shanghai 447
Rome 428
Belize City 400
Salt Lake City 377
Atlanta 346
Bologna 329
Tokyo 302
Munich 272
Da Nang 267
Falls Church 257
Dublin 239
Frankfurt am Main 224
Toronto 221
Nuremberg 216
Rio de Janeiro 212
Haiphong 211
Amsterdam 204
Fremont 191
Redondo Beach 190
Las Vegas 188
Guangzhou 180
Naples 177
Perth 170
Phoenix 170
Saint Louis 169
Norwalk 166
Orem 159
Belo Horizonte 156
Miano 154
Kent 151
North Bergen 148
Tampa 147
Lappeenranta 145
Brooklyn 143
Albuquerque 141
Tashkent 139
Elk Grove Village 135
Montreal 135
Baghdad 132
Kunming 132
Philadelphia 121
San Francisco 121
Nanjing 120
Redwood City 120
Johannesburg 119
Mexico City 115
Florence 109
Brasília 107
Curitiba 104
Miami 103
Kilburn 100
Charlotte 99
Denver 99
Vienna 99
Totale 165.525
Salva come PNG Salva come JPEG
Nome #
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 2.651
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.494
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 2.469
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 2.415
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 2.164
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 2.096
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.094
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 2.082
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 2.077
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 2.075
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 717
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 657
La sindrome da pacemaker. 606
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 604
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) 598
A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. 537
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 523
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 522
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 502
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 501
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 468
A prospective randomized evaluation of VV delay optimization in CRT patients. Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques 436
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation 432
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 404
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 383
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 381
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 361
Radar-Based Monitoring of Vital Signs: A Tutorial Overview 350
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 350
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 350
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 349
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 344
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 344
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 343
Atrial fibrillation: Adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. 341
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 340
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 339
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 337
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 333
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 332
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 331
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA) 325
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing) 321
Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies 319
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 316
Clinically guided pacemaker choice and setting: pacemaker expert programming study 310
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 310
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 308
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics 306
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 306
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 305
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 305
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 304
Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry 304
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis 304
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 302
Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes 301
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 300
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 299
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 298
Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 297
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 296
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 296
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 296
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 295
Holter ECG for pacemaker/defibrillator carriers: What is its role in the era of remote monitoring? 294
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 294
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 293
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 292
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 291
Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection 291
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry 290
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 290
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 290
The wearable cardioverter-defibrillator: Current technology and evolving indications 290
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 289
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 289
Drug management of atrial fibrillation in light of guidelines and current evidence: an Italian Survey on behalf of Italian Association of Arrhythmology and Cardiac Pacing 288
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) 288
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 288
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA 288
Heart failure after myocardial revascularization: Risk markers 287
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 287
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 287
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 286
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy 286
Determinants of all-cause mortality in different age groups in patients with severe systolic left ventricular dysfunction receiving an implantable cardioverter defibrillator (from the Italian ClinicalService Multicenter Observational Project) 286
Health economics and the European Heart Rhythm Association. 285
Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 285
Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers 284
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 283
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 281
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 281
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 280
DIGItal Health Literacy after COVID-19 Outbreak among Frail and Non-Frail Cardiology Patients: The DIGI-COVID Study 279
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 279
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 278
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 278
Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT 278
Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE 277
Totale 53.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 859.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 859.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202533.713 1.151 386 730 1.788 4.911 5.146 3.766 2.148 4.150 2.542 3.045 3.950
2025/202683.486 3.554 1.887 5.259 4.812 5.374 9.122 9.842 3.735 24.539 4.807 5.986 4.569
2026/20272.695 2.695 0 0 0 0 0 0 0 0 0 0 0
Totale 226.472